Gepke Visser
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Gepke Visser has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
G. Peter A. Smit
University Hospital
4 shared publicationsKurt Ullrich
University Hospital
4 shared publicationsPhilippe Labrune
Hôpital Antoine-Béclère
4 shared publicationsShimon Moses
Soroka Medical Centre
4 shared publicationsUdo Wendel
University Hospital
4 shared publicationsJames V. Leonard
Great Ormond Street Hospital
3 shared publications
Latest Publications
- 1 October 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S120-S123
Consensus guidelines for management of glycogen storage disease type 1b—European study on glycogen storage disease type 1
- 1 October 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S120-S123
Consensus guidelines for management of glycogen storage disease type 1b—European study on glycogen storage disease type 1
- 1 October 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S83-S87
Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European study on glycogen storage disease type 1
- 1 October 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S83-S87
Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European study on glycogen storage disease type 1
- 1 June 2002
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 25 (4) , 261-267
Intestinal function in glycogen storage disease type I
Glycogen storage disease type I (GSD I) (McKusick 232200) is caused by inherited defects of the glucose‐6‐phosphatase complex. Patients with GSD Ia as well as patients with GSD Ib may suffer from intermittent diarrhoea, which seems to worsen with age. The cause of this diarrhoea is unknown. This study describes the results of investigations of intestinal functions and morphology in patients with GSD Ia and GSD Ib, which were performed to detect a common cause for chronic diarrhoea in GSD I. The following were investigated: faecal fat excretion, faecal α1‐antitrypsin and faecal chymotrypsin, expiratory H2 concentrations, persorption of cornstarch in urine and colonic biopsies. With the investigations presented in this study, no common cause for diarrhoea in GSD I was found. In GSD Ib loss of mucosal barrier function due to inflammation, documented by increased faecal α1‐antitrypsin excretion (3.5–9.6 mg/g dry faeces) and inflammation in the colonic biopsies, seems to be the main cause. The inflammation is most likely related to disturbed neutrophil function, which is often found in GSD Ib. Whether another cause is involved in GSD Ia and in GSD Ib, related to the disturbed function of glucose‐6‐phosphatase in the enterocyte, remains to be investigated.
- 1 June 2002
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 25 (4) , 261-267
Intestinal function in glycogen storage disease type I
Glycogen storage disease type I (GSD I) (McKusick 232200) is caused by inherited defects of the glucose‐6‐phosphatase complex. Patients with GSD Ia as well as patients with GSD Ib may suffer from intermittent diarrhoea, which seems to worsen with age. The cause of this diarrhoea is unknown. This study describes the results of investigations of intestinal functions and morphology in patients with GSD Ia and GSD Ib, which were performed to detect a common cause for chronic diarrhoea in GSD I. The following were investigated: faecal fat excretion, faecal α1‐antitrypsin and faecal chymotrypsin, expiratory H2 concentrations, persorption of cornstarch in urine and colonic biopsies. With the investigations presented in this study, no common cause for diarrhoea in GSD I was found. In GSD Ib loss of mucosal barrier function due to inflammation, documented by increased faecal α1‐antitrypsin excretion (3.5–9.6 mg/g dry faeces) and inflammation in the colonic biopsies, seems to be the main cause. The inflammation is most likely related to disturbed neutrophil function, which is often found in GSD Ib. Whether another cause is involved in GSD Ia and in GSD Ib, related to the disturbed function of glucose‐6‐phosphatase in the enterocyte, remains to be investigated.
- 1 January 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S83-S87
Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1
Patients with glycogen storage disease type 1b (GSD-1b) have neutropenia and neutrophil dysfunction that predispose to frequent infections and inflammatory bowel disease (IBD), for which granulocyte colony-stimulating factor (GCSF) is given. To investigate the use and the value of GCSF treatment in GSD-1b, a retrospective registry of GSD-1 patients born between 1960 and 1995 in 12 European countries was established. Included were 57 GSD-1b patients. Unglycosylated GCSF was given to 18 patients, median age of starting therapy was 8 years, longest duration of therapy 7 years. Dose varied between 2–10 µg/kg, with a frequency from daily to twice per week. Neutropenia (defined as an absolute neutrophil count 9/l) was found in 49 patients. In untreated patients, a significant decrease of haemoglobin, platelet counts and leucocyte counts with increasing age (PPPConclusion: in this retrospective study a significant haematological effect was documented and a subjective improvement of infections and inflammatory bowel disease. In view of the uncertainty, prospective controlled trials seem warranted to clarify the indication for the use of granulocyte colony-stimulating factor in this disease.
- 1 January 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S83-S87
Granulocyte colony-stimulating factor in glycogen storage disease type 1b. Results of the European Study on Glycogen Storage Disease Type 1
Patients with glycogen storage disease type 1b (GSD-1b) have neutropenia and neutrophil dysfunction that predispose to frequent infections and inflammatory bowel disease (IBD), for which granulocyte colony-stimulating factor (GCSF) is given. To investigate the use and the value of GCSF treatment in GSD-1b, a retrospective registry of GSD-1 patients born between 1960 and 1995 in 12 European countries was established. Included were 57 GSD-1b patients. Unglycosylated GCSF was given to 18 patients, median age of starting therapy was 8 years, longest duration of therapy 7 years. Dose varied between 2–10 µg/kg, with a frequency from daily to twice per week. Neutropenia (defined as an absolute neutrophil count 9/l) was found in 49 patients. In untreated patients, a significant decrease of haemoglobin, platelet counts and leucocyte counts with increasing age (PPPConclusion: in this retrospective study a significant haematological effect was documented and a subjective improvement of infections and inflammatory bowel disease. In view of the uncertainty, prospective controlled trials seem warranted to clarify the indication for the use of granulocyte colony-stimulating factor in this disease.
- 1 January 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S120-S123
Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1
- 1 January 2002
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 161 (1) , S120-S123
Consensus guidelines for management of glycogen storage disease type 1b - European Study on Glycogen Storage Disease Type 1
- 20 November 2000
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 159 (12) , 901-904
3-methylcrotonyl-CoA carboxylase deficiency in an infant with cardiomyopathy, in her brother with developmental delay and in their asymptomatic father.
- 20 November 2000
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 159 (12) , 901-904
3-methylcrotonyl-CoA carboxylase deficiency in an infant with cardiomyopathy, in her brother with developmental delay and in their asymptomatic father.
- 1 January 1999
- Published by Hindawi Limited in Human Mutation
- Vol. 13 (2) , 173
Glycogen storage disease type Ia: Four novel mutations (175delGG, R170X, G266V and V338F) identified
Deficient activity of glucose-6-phosphatase (G6Pase) causes glycogen storage disease type Ia (GSD Ia). We analysed the G6Pase gene of 16 GSD Ia patients using single strand conformation polymorphism (SSCP) analysis prior to automated sequencing of exon(s) revealing an aberrant SSCP pattern. In all GSD Ia patients we were able to identify mutations on both alleles of the G6Pase gene, indicating that this method is a reliable procedure to identify mutations. Four novel mutations (175delGG, R170X, G266V and V338F) were identified.
- 1 January 1999
- Published by Hindawi Limited in Human Mutation
- Vol. 13 (2) , 173
Glycogen storage disease type Ia: Four novel mutations (175delGG, R170X, G266V and V338F) identified
Deficient activity of glucose-6-phosphatase (G6Pase) causes glycogen storage disease type Ia (GSD Ia). We analysed the G6Pase gene of 16 GSD Ia patients using single strand conformation polymorphism (SSCP) analysis prior to automated sequencing of exon(s) revealing an aberrant SSCP pattern. In all GSD Ia patients we were able to identify mutations on both alleles of the G6Pase gene, indicating that this method is a reliable procedure to identify mutations. Four novel mutations (175delGG, R170X, G266V and V338F) were identified.